Afficher la couverture 'Pooled safety analysis and management of sotorasib-related adverse events in <i>KRAS</i> G12C-mutated advanced non-small cell lung cancer | Skoulidis, Ferdinandos' en grand format
/5

0 avis

Pooled safety analysis and management of sotorasib-related adverse events in KRAS G12C-mutated advanced non-small cell lung cancer

Archive ouverte

Skoulidis, Ferdinandos | Li, Bob, T | Hochmair, Maximilian | Govindan, Ramaswamy | Vincent, Mark | van der Wekken, Anthonie, J | Reguart Aransay, Noemi | O’byrne, Kenneth, J | Girard, Nicolas | Griesinger, Frank | Nishio, Makoto | Häfliger, Simon | Lindsay, Colin | Reinmuth, Niels | Paulus, Astrid | Papakotoulas, Pavlos | Kim, Sang-We | Ferreira, Carlos, Gil | Pasello, Giulia | Duruisseaux, Michaël | Gennatas, Spyridon | Dimou, Anastasios | Mehta, Bhakti | Kormany, William | Nduka, Chidozie | Sylvester, Brooke, E | Ardito-Abraham, Christine | Wang, Yang | de Langen, Adrianus, Johannes

Edité par CCSD ; Oxford University Press -

International audience.

Introduction:

We describe the safety of sotorasib monotherapy in patients with KRAS G12C-mutated advanced non-small cell lung cancer (NSCLC) and discuss practical recommendations for managing key risks.

Methods:

Incidence rates of treatment-related adverse events (TRAEs) were pooled from 4 clinical trials: CodeBreaK 100 (NCT03600883), CodeBreaK 101 (NCT04185883), CodeBreaK 105 (NCT04380753), and CodeBreaK 200 (NCT04303780) and graded according to CTCAE v5.0. Adverse events were deemed sotorasib-related per investigator causality assessment.

Suggestions

Du même auteur

Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial

Archive ouverte | de Langen, Adrianus Johannes | CCSD

International audience

Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study

Archive ouverte | Garassino, Marina, Chiara | CCSD

International audience. has a patent T-cell immunotherapy development pending; is a founder and owner of BioCytics, which is a clinical research laboratory developing T-cell immunotherapy; and has previously bought ...

Sotorasib (960 mg or 240 mg) once daily in patients with previously treated KRAS G12C-mutated advanced NSCLC

Archive ouverte | Hochmair, Maximilian J. | CCSD

International audience. Background: Sotorasib 960 mg once daily is approved to treat KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC). Sotorasib exhibits non-dose proportional phar...

Chargement des enrichissements...